Trevena reported a net loss attributable to common stockholders of $4.9 million, or $5.79 per share, compared to $7.9 million, or $14.20 per share in the third quarter of 2023. Cash and cash equivalents were $13.5 million as of September 30, 2024.

Trevena reported a net loss of $17.1 million for the second quarter of 2024. The company is focusing on the commercialization of OLINVYK and advancing its pipeline, including TRV027 for acute lung injury and TRV250 for acute migraine.

Trevena reported its financial results for the third quarter ended September 30, 2023. The company reported promising proof-of-concept data for its two TRV045 studies, including favorable safety and tolerability topline data, and strengthened its balance sheet with the receipt of the $15 million R-Bridge tranche.

Trevena reported net revenue of $3.0 million and a net loss attributable to common stockholders of $8.0 million, or $0.69 per share, for the second quarter of 2023. They anticipate a $15 million non-dilutive tranche from R-Bridge in Q3 2023.

Trevena reported a net loss of $15.3 million for Q3 2022. The company's cash balance was $40.4 million as of September 30, 2022, expected to fund operations into Q3 2023. OLINVYK commercialization progressed and positive Phase 1 data was reported for TRV045.

Trevena reported a net loss attributable to common stockholders of $15.0 million, or $0.09 per share, for the second quarter of 2022. Cash and cash equivalents were $49.5 million as of June 30, 2022, which the Company believes will be sufficient to fund the Company’s operating expenses and capital expenditure requirements to mid-2023.

Trevena reported a net loss of $14.0 million for the second quarter of 2021, driven by increased commercialization activities for OLINVYK. Cash and cash equivalents were $91.0 million as of June 30, 2021, expected to fund operations through YE 2022.

Trevena, Inc. reported a net loss attributable to common stockholders of $11.9 million, or $0.08 per share, for the fourth quarter of 2020. Year-end cash and cash equivalents were $109.4 million as of December 31, 2020, which the Company believes will be sufficient to fund the Company’s operating expenses and capital expenditure requirements through the fourth quarter of 2022.

Trevena announced FDA approval of OLINVYK for acute pain management and expects product availability in Q4 2020. The company reported $54.8 million in cash and cash equivalents as of June 30, 2020, sufficient to fund operations through year-end 2021.

Trevena reported a net loss of $5.7 million for the first quarter of 2020. The company's cash and cash equivalents were $28.1 million at the end of the quarter, expected to fund operations into the first quarter of 2021. The FDA's review of the oliceridine NDA resubmission is ongoing with a decision expected by August 7.

Trevena reported a net loss attributable to common stockholders of $6.4 million, or $0.07 per share, for the fourth quarter of 2019. The company's cash, cash equivalents, and marketable securities were $35.8 million at December 31, 2019.